reports
Hudson Pacific Properties Inc: 1 director
A director at Hudson Pacific Properties Inc sold 127,918 shares at 5.720USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...
HomeTrust Bank Awarded Newsweek’s Most Loved Workplace Certification
HomeTrust Bank Awarded Newsweek’s Most Loved Workplace Certification ASHEVILLE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank” or “HTB”), today announced that the Bank received a coveted Most Loved Workplace 2024 certification by Newsweek. Created in partnership with the Best Practices Institute, the annual ranking pays tribute to companies that put respect, caring and appreciation for employees at the center of their business model. “We are extremely proud to have HTB recognized by this distingu...
HomeTrust Bancshares, Inc. Recognized in Two Renowned Bank Rankings
HomeTrust Bancshares, Inc. Recognized in Two Renowned Bank Rankings ASHEVILLE, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank” or “HTB”), today announced that the Bank received top honors in two nationally recognized bank rankings. HomeTrust has been named a Top 50 Community Bank in S&P Global Market Intelligence’s annual rankings for 2023’s Best-Performing Large Community Banks with assets between $3 billion and $10 billion. HomeTrust also ranked in the top 100 of Forbes 15th Annual Best Banks l...
HomeTrust Bancshares, Inc. Announces Financial Results for the First Q...
HomeTrust Bancshares, Inc. Announces Financial Results for the First Quarter of the Year Ending December 31, 2024, Declaration of a Quarterly Dividend, and Re-Authorization of Stock Buyback Program ASHEVILLE, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (NASDAQ: HTBI) ("Company"), the holding company of HomeTrust Bank ("Bank"), today announced preliminary net income for the first quarter of the year ending December 31, 2024 and approval of its quarterly cash dividend. In addition, on April 22, 2024, the Company's Board of Directors re-authorized the repurchase the r...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial R...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pi...
Agile Therapeutics Announces Delisting from Nasdaq
Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of a...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial resu...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financi...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Bu...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors (“Perceptive”). This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which ori...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gro...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of comm...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Pane...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to $31.5 Million, a Decrease of 47% to 44% C...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PBF PBF ENERGY INC. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CVI CVR ENERGY INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
HTBI HOMETRUST BANCSHARES INC
MOG.A MOOG INC. CLASS A
AXP AMERICAN EXPRESS COMPANY
COF CAPITAL ONE FINANCIAL CORPORATION
ISTR INVESTAR HOLD
PVH PVH CORP.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
KALV KALVISTA PHARMACEUTICALS
GLOB GAZIT-GLOBE LTD.
AOUT AMERICAN OUTDOOR BRANDS
NKTX INC.
WMG NKARTA
ABNB WARNER MUSIC GROUP CORP. CLASS A
EYPT AIRBNB INC. CLASS A
PSFE EYEPOINT PHARMACEUTICALS
VERA PAYSAFE LTD.
EWTX VERA THERAPEUTICS INC
LBTYA EDGEWISE THERAPEUTICS INC
AEON LIBERTY GLOBAL PLC
AEON BIOPHARMA INC
HomeTrust Bancshares, Inc. Announces Financial Results for the Second ...
HomeTrust Bancshares, Inc. Announces Financial Results for the Second Quarter of the Six-Month Transition Period Ending December 31, 2023* and Quarterly Dividend ASHEVILLE, N.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (NASDAQ: HTBI) ("Company"), the holding company of HomeTrust Bank ("Bank"), today announced preliminary net income for the second quarter of the six-month transition period ended December 31, 2023* and approval of its quarterly cash dividend. For the quarter ended December 31, 2023 compared to the quarter ended September 30, 2023: net income was $13.5...
Hybridan Small Cap Feast - 23 Jan 24
23nd January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje...
The Biden-Harris Administration Announces New Guidance to Enable Expan...
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in President Biden’s June 2023 Executive Order The Company Commends the Administration for their Continued Commitment to Reproductive Health PRINCETON, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE)...
HomeTrust Bancshares, Inc. Announces Retirement of Its Chief Credit Of...
HomeTrust Bancshares, Inc. Announces Retirement of Its Chief Credit Officer and Appointment of Successor ASHEVILLE, N.C., Jan. 23, 2024 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank” or “HTB”), today announced that Keith J. Houghton, Executive Vice President and Chief Credit Officer, will be retiring from his position effective June 30, 2024. As part of the Bank’s strategic succession plan, Kevin Nunley, Senior Vice President and Director of Commercial Credit, will assume the role and responsibilities of Chief Credi...
Cormedix Inc: 1 director
A director at Cormedix Inc bought 6,000 shares at 3.375USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthe...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in President Biden’s June 2023 Executive Order Implementation of the Committee’s Recommendation Could Potentially Eliminate Financial Barriers for Contraceptive Products like...
SmartRent Inc: 1 director
A director at SmartRent Inc bought 85,149 shares at 2.917USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.